Last 15 quarters of trend data · Healthcare · Cell & Gene Therapy
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -37.40 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 1087.01 | 981.93 | 1354.06 | 1320.46 | 345.57 | 463.79 | — | 8970.36 | 1019.21 | 14728.68 | 4739.02 | 1382.62 | — | — | — | — |
| — | +111.7% | — | -85.3% | -66.1% | -96.9% | — | +548.8% | — | — | — | — | — | — | — | — | |
| P/B Ratio | 7.81 | 6.36 | 6.09 | 5.24 | 4.26 | 4.49 | 2.96 | 2.65 | 2.53 | 4.72 | 3.81 | 5.14 | — | — | — | — |
| — | +41.4% | +106.0% | +97.9% | +68.2% | -4.8% | -22.4% | -48.5% | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -15.0% | -66.4% | -239.2% | -173.5% | -25.5% | 5.3% | — | -52721.2% | -5777.2% | -45532.6% | -16539.6% | 99.2% | -300.0% | -130288.9% | -3942.3% | — |
| — | -1342.9% | — | +99.7% | +99.6% | +100.0% | — | -53222.8% | -1825.7% | +65.1% | -319.5% | — | — | — | — | — | |
| Operating Margin | -4722.1% | -3943.2% | -7467.7% | -6130.1% | -2097.3% | -3069.0% | — | -81161.5% | -8344.1% | -65802.3% | -23291.0% | -4247.4% | -1893200.0% | -156033.3% | -5010.8% | — |
| — | -28.5% | — | +92.4% | +74.9% | +95.3% | — | -1810.8% | +99.6% | +57.8% | -364.8% | — | — | — | — | — | |
| Net Margin | -3985.0% | — | -6832.8% | -5558.8% | -1779.0% | -2629.5% | — | -66253.8% | -6973.2% | -47453.5% | -17028.8% | -3200.8% | -1611600.0% | -130755.6% | -4467.5% | — |
| — | — | — | +91.6% | +74.5% | +94.5% | — | -1969.9% | +99.6% | +63.7% | -281.2% | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -21.7% | — | -7.5% | -6.5% | -5.7% | -6.5% | -6.0% | -4.8% | -5.0% | -3.7% | -3.4% | -4.5% | -8.4% | -7.2% | -6.9% | -6.7% |
| — | — | -23.7% | -36.3% | -14.6% | -72.2% | -78.7% | -6.6% | +40.2% | +48.3% | +51.3% | +33.0% | — | — | — | — | |
| ROA | -20.8% | — | -7.1% | -6.2% | -5.4% | -6.1% | -5.8% | -4.6% | -4.9% | -3.7% | -3.3% | -4.4% | -7.8% | -5.6% | — | -5.7% |
| — | — | -22.8% | -34.5% | -11.6% | -67.5% | -75.3% | -6.8% | +37.9% | +34.2% | — | +23.4% | — | — | — | — | |
| ROIC | -23.8% | -4.8% | -6.2% | -5.6% | -5.3% | -5.9% | -5.5% | -5.5% | -5.9% | -4.2% | -3.8% | -5.0% | -7.7% | -4.6% | -4.5% | — |
| — | +18.8% | -12.4% | -0.1% | +9.8% | -41.2% | -45.5% | -10.2% | +23.8% | +9.5% | +16.1% | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | — | 0.13 |
| — | -11.5% | +477.8% | +372.0% | +2770.5% | +1811.1% | +130.6% | +107.0% | -94.2% | -78.7% | — | -99.4% | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 24.63 | 21.70 | 22.22 | 31.30 | 24.63 | 22.79 | 22.15 | 30.97 | 35.30 | 35.32 | 47.57 | 57.95 | 13.62 | 17.92 | — | 9.54 |
| — | -4.8% | +0.3% | +1.1% | -30.2% | -35.5% | -53.4% | -46.6% | +159.2% | +97.1% | — | +507.4% | — | — | — | — | |
| Quick Ratio | 24.58 | 21.68 | 22.20 | 31.25 | 24.58 | 22.74 | 22.15 | 30.97 | 35.30 | 35.32 | 47.57 | 57.95 | 13.62 | 17.92 | — | 9.54 |
| — | -4.7% | +0.2% | +0.9% | -30.4% | -35.6% | -53.4% | -46.6% | +159.2% | +97.1% | — | +507.4% | — | — | — | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 15 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CGON stock.
CG Oncology Inc.'s current P/E is -37.4x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
CG Oncology Inc.'s current operating margin is -4722.1%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking CG Oncology Inc.'s business trajectory between earnings reports.